Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03539107 · ClinicalTrials.gov registry record · NA

Voiding Assessment Based on Minimum Spontaneous Void of 150 mL Compared to Retrograde Fill Method After Female Pelvic Floor Reconstructive Surgery

A NA study of Urinary Incontinence and Pelvic Organ Prolapse, sponsored by Yale University.

Completed
Registry status
NA
Development phase
110
Enrollment target
1
Study location

NCT03539107 is a NA study of Urinary Incontinence and Pelvic Organ Prolapse that has completed, run by Yale University. The registered enrollment target is 110 participants, below the 260-participant average among 48 other Urinary Incontinence trials with a reported enrollment target (58% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03539107, a NA study of Urinary Incontinence and Pelvic Organ Prolapse, has completed, sponsored by Yale University.

COMPLETED
Registry status
NA
Development phase
110 participants
Enrollment target
1
Study location

Study Summary

This study will compare voiding assessment based on a minimum spontaneous voided volume of 150 cc with the standard retrograde fill approach in women after pelvic floor procedures.

Interventions

  • PROCEDURE Retrograde bladder fill
  • OTHER spontaneous void

Study Locations (1)

Connecticut

  • Yale University - New Haven

Trial Details

FieldValue
Enrollment Target 110 participants
Start Date 2019-09-01
Est. Completion 2019-12-20
Phase NA

Sponsor

Yale University

1,492 total trials

What the Registry Record Tells You About NCT03539107

The ClinicalTrials.gov registry entry for NCT03539107 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 110 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 260-participant average among 48 other Urinary Incontinence trials with a reported enrollment target (58% lower). The listed sponsor is Yale University, which has 1,492 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Urinary Incontinence appearing as the primary indexed condition, and to 2 interventions - of which Retrograde bladder fill is the first listed.

NCT03539107 reports 1 study location spanning 1 distinct geographic area - top geographies include Connecticut.

Frequently Asked Questions

What is clinical trial NCT03539107 about?

NCT03539107 is a clinical study titled "Voiding Assessment Based on Minimum Spontaneous Void of 150 mL Compared to Retrograde Fill Method After Female Pelvic Floor Reconstructive Surgery". This study will compare voiding assessment based on a minimum spontaneous voided volume of 150 cc with the standard retrograde fill approach in women after pelvic floor procedures.

What is the current status of trial NCT03539107?

This trial is currently completed. It is a NA study. The enrollment target is 110 participants. The study started on 2019-09-01. Estimated completion is 2019-12-20.

What conditions does trial NCT03539107 study?

This clinical trial studies the following conditions: Urinary Incontinence, Pelvic Organ Prolapse.

What interventions are being tested in trial NCT03539107?

The interventions under investigation include: Retrograde bladder fill (PROCEDURE), spontaneous void (OTHER).

Who is sponsoring clinical trial NCT03539107?

This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03539107 being conducted?

This trial has 1 study location across Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Urinary Incontinence

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.